INSIGHTEC Closes $150 Million Series E Financing

PR72118

HAIFA, Israel and MIAMI, January 31, 2018 /PRNewswire=KYODO JBN/ --

    INSIGHTEC, a commercial-stage medical technology company revolutionizing

surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced

today the closing of a $150 million Series E private equity investment round.

Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on

finding and funding innovative and emerging companies, led the round with a

$100 million investment.

    INSIGHTEC plans to use the proceeds from the financing to support marketing

and commercialization for its approved safe and non-invasive treatments,

including Exablate(R) Neuro for essential tremor (ET), and for continuing

research and development towards addressing other brain indications including

Parkinson's disease, Alzheimer's disease, and cancer.

    "INSIGHTEC is committed to driving global adoption of our existing focused

ultrasound treatments, while leading ground-breaking research to apply our

proprietary technology in novel ways," said Maurice R. Ferré, MD, INSIGHTEC's

Chief Executive Officer and Chairman of the Board. "With this substantial

investment, we plan to ultimately leverage our incisionless solutions to

positively transform the lives of millions of patients."

    INSIGHTEC's Exablate Neuro is the first focused ultrasound device approved

by the FDA to safely and non-invasively treat ET in patients that have not

responded to medication. Neurosurgeons use the INSIGHTEC device in an

incisionless procedure that delivers focused ultrasound beams to the target

deep in the brain. Where the beams converge, the temperature rises causing

thermal ablation, monitored in real-time with MR imaging. Many patients who

have undergone the non-invasive treatment report immediate and lasting relief

from their tremor and improved quality of life. There are currently more than

forty medical centers around the world treating ET patients and developing

future applications with incisionless MRgFUS.

    KDT joins existing INSIGHTEC investors including Elbit Imaging, York

Capital, Exigent Capital Group, GE Healthcare, GEOC, and Meditech Advisors.

    About INSIGHTEC

    INSIGHTEC is the world leader and innovator of MRI-guided Focused

Ultrasound. The company's non-invasive therapy platforms, Exablate and Exablate

Neuro, are proven technology based on sound clinical evidence for treating

essential tremor, painful bone metastases and uterine fibroids. The company is

dedicated to improving patient lives by collaborating with physicians, medical

institutions, academic researchers and regulatory bodies around the world.

INSIGHTEC is headquartered in Haifa, Israel, and Miami, with offices in Dallas,

Tokyo and Shanghai.

    "Exablate," as well as the "INSIGHTEC" logo, whether standing alone or in

connection with the word " INSIGHTEC" are protected trademarks of INSIGHTEC.

    For more information, please visit: http://www.insightec.com.

    MEDIA CONTACT:

    MICHELLE BARRY

    Red Lorry Yellow Lorry for INSIGHTEC

    insightec@rlyl.com

    +1-(857)-217-2886

Source: INSIGHTEC